TDMS Study 99035-01 Pathology Tables
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: 556-52-5
Lock Date: 09/24/01
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) FEMALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 15 15 15 15 15
Early Deaths
Moribund Sacrifice 2 1 2 1 4
Natural Death 1 2
Survivors
Terminal Sacrifice 13 14 12 14 9
Animals Examined Microscopically 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%)
Intestine Large, Rectum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%)
Intestine Small, Duodenum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 4 (27%) 1 (7%) 1 (7%)
Intestine Small, Jejunum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 3 (20%) 3 (20%) 1 (7%)
Intestine Small, Ileum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 2 (13%) 2 (13%) 1 (7%) 1 (7%)
Liver (15) (15) (15) (15) (15)
Histiocytic Sarcoma 5 (33%) 1 (7%) 8 (53%) 5 (33%) 8 (53%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (7%)
Mesentery (2)
Histiocytic Sarcoma 2 (100%)
Stomach, Forestomach (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%)
Squamous Cell Papilloma 1 (7%) 3 (20%)
Stomach, Glandular (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%) 2 (13%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 2 (13%) 2 (13%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) FEMALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (15) (15) (15) (15) (15)
Histiocytic Sarcoma 3 (20%) 7 (47%) 2 (13%) 1 (7%)
Adrenal Medulla (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%)
Pituitary Gland (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 2 (13%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (15) (15) (15) (15) (15)
Histiocytic Sarcoma 8 (53%) 5 (33%) 8 (53%) 6 (40%) 5 (33%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (7%)
Uterus (15) (15) (15) (15) (15)
Hemangiosarcoma, Metastatic, Spleen 1 (7%)
Histiocytic Sarcoma 4 (27%) 4 (27%) 5 (33%)
Sarcoma Stromal 1 (7%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (15) (15) (15) (15) (15)
Hemangiosarcoma 1 (7%)
Histiocytic Sarcoma 9 (60%) 8 (53%) 11 (73%) 8 (53%) 8 (53%)
Lymph Node (13) (15) (15) (13) (14)
Lumbar, Histiocytic Sarcoma 2 (13%) 1 (7%) 2 (14%)
Mediastinal, Histiocytic Sarcoma 1 (8%) 1 (7%) 6 (40%) 3 (23%) 3 (21%)
Pancreatic, Histiocytic Sarcoma 1 (7%)
Renal, Histiocytic Sarcoma 2 (13%) 1 (7%)
Lymph Node, Mandibular (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%) 6 (40%) 2 (13%) 3 (20%)
Lymph Node, Mesenteric (15) (15) (15) (15) (15)
Histiocytic Sarcoma 3 (20%) 3 (20%) 5 (33%) 3 (20%) 5 (33%)
Spleen (15) (15) (15) (15) (15)
Hemangiosarcoma 1 (7%)
Histiocytic Sarcoma 2 (13%) 2 (13%) 7 (47%) 3 (20%) 2 (13%)
Page 3
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) FEMALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymus (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%) 6 (40%) 2 (13%) 2 (13%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15)
Subcutaneous Tissue, Hemangiosarcoma 1 (7%)
Subcutaneous Tissue, Histiocytic Sarcoma 2 (13%) 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2)
Histiocytic Sarcoma 2 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (15) (15) (15) (15) (15)
Choristoma 1 (7%)
Histiocytic Sarcoma 1 (7%) 4 (27%) 4 (27%) 2 (13%)
Spinal Cord (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15)
Alveolar/Bronchiolar Adenoma 1 (7%) 1 (7%) 4 (27%)
Alveolar/Bronchiolar Carcinoma 1 (7%)
Histiocytic Sarcoma 2 (13%) 6 (40%) 3 (20%) 6 (40%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) FEMALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 4 (27%) 2 (13%) 3 (20%)
Urinary Bladder (15) (15) (15) (15) (15)
Histiocytic Sarcoma 2 (13%) 2 (13%) 2 (13%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(15) *(15) *(15) *(15) *(15)
Histiocytic Sarcoma 9 (60%) 9 (60%) 12 (80%) 10 (67%) 13 (87%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) FEMALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 10 9 12 12 14
Total Primary Neoplasms 10 10 13 14 23
Total Animals with Benign Neoplasms 1 2 7
Total Benign Neoplasms 1 2 7
Total Animals with Malignant Neoplasms 10 9 12 11 14
Total Malignant Neoplasms 10 9 13 12 15
Total Animals with Metastatic Neoplasms 1 1
Total Metastatic Neoplasm 3 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) MALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 15 15 15 15 15
Early Deaths
Natural Death 2 1 1 1 3
Moribund Sacrifice 1 4
Dosing Accident 1
Survivors
Terminal Sacrifice 13 14 13 14 7
Animals Examined Microscopically 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%)
Intestine Large, Cecum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%)
Intestine Small, Duodenum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 2 (13%)
Intestine Small, Jejunum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 2 (13%) 1 (7%)
Intestine Small, Ileum (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%)
Liver (15) (15) (15) (15) (15)
Histiocytic Sarcoma 2 (13%) 2 (13%) 4 (27%) 2 (13%) 10 (67%)
Pancreas (1)
Histiocytic Sarcoma 1 (100%)
Stomach, Forestomach (15) (15) (15) (15) (15)
Squamous Cell Papilloma, Multiple 1 (7%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 5 (33%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) MALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (15) (15) (15) (14) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%)
Pituitary Gland (15) (15) (14) (15) (15)
Histiocytic Sarcoma 1 (7%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (15) (15) (15) (15) (15)
Histiocytic Sarcoma 2 (13%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (15) (15) (15) (15) (15)
Histiocytic Sarcoma 2 (13%) 5 (33%) 6 (40%) 4 (27%) 8 (53%)
Lymph Node (14) (14) (15) (13) (13)
Mediastinal, Histiocytic Sarcoma 1 (7%) 3 (20%) 7 (54%)
Mediastinal, Osteosarcoma, Metastatic, Skin 1 (7%)
Lymph Node, Mandibular (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%) 2 (13%) 3 (20%)
Lymph Node, Mesenteric (15) (15) (15) (14) (15)
Histiocytic Sarcoma 1 (7%) 2 (13%) 1 (7%) 5 (33%)
Spleen (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%) 3 (20%) 1 (7%) 7 (47%)
Thymus (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 2 (13%) 2 (13%) 4 (27%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15)
Osteosarcoma 1 (7%)
Squamous Cell Papilloma 1 (7%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) MALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 1 (7%) 1 (7%) 4 (27%)
Spinal Cord (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15)
Alveolar/Bronchiolar Adenoma 1 (7%) 2 (13%) 5 (33%) 2 (13%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (13%) 1 (7%)
Alveolar/Bronchiolar Carcinoma 2 (13%) 1 (7%) 3 (20%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (7%)
Histiocytic Sarcoma 1 (7%) 1 (7%) 2 (13%) 2 (13%) 6 (40%)
Osteosarcoma, Metastatic, Skin 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15)
Histiocytic Sarcoma 1 (7%) 2 (13%) 2 (13%) 5 (33%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(15) *(15) *(15) *(15) *(15)
Histiocytic Sarcoma 2 (13%) 6 (40%) 9 (60%) 5 (33%) 11 (73%)
Lymphoma Malignant 2 (13%) 1 (7%)
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) MALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(15) *(15) *(15) *(15) *(15)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 99035-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: 26-39 WEEKS TRANSGENIC MODEL EVALUATION II (GLYCIDOL) Date: 03/31/04
Route: GAVAGE Time: 12:54:57
____________________________________________________________________________________________________________________________________
P16(INK4A)/(+/-) (C57BL/6) MALE 0 MG/KG 25 MG/KG 50 MG/KG 100 200
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 7 8 12 12 12
Total Primary Neoplasms 8 9 12 17 15
Total Animals with Benign Neoplasms 1 2 2 7 4
Total Benign Neoplasms 1 2 2 7 4
Total Animals with Malignant Neoplasms 6 7 10 9 11
Total Malignant Neoplasms 7 7 10 10 11
Total Animals with Metastatic Neoplasms 1
Total Metastatic Neoplasm 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------